Momelotinib Effectiveness in Myelofibrosis

ConditionMyelofibrosis (MF)

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorGruppo Italiano Malattie EMatologiche dell'Adulto

About this trial

Observational study aimed at evaluating the use of momelotinib in patients with primary or post polycythemia vera (PV) or post essential thrombocythemia myelofibrosis (post-ET MF) in a real-world setting.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients aged 18 years or older.

Patients diagnosed with primary or post-polycythemia vera/post-essential thrombocythemia myelofibrosis start treatment with MMB according to clinical practice from AIFA authorization.

Patients with palpable splenomegaly at baseline of momelotinib treatment.

Informed consent signed, if applicable.

Disqualifiers

Diagnosis of MPN, unclassifiable, myelodysplastic/myeloproliferative neoplasms, myelodysplastic syndromes, essential thrombocythemia, polycythemia vera.

Accelerated/blast phase of MF.

Patients with platelets <20 x10(9)/L at baseline of MMB treatment.

Patients JAK inhibitors-exposed for other diseases apart from MF.

Trial population

Patients treated for primary myelofibrosis or post polycythemia vera or post essential thrombocythemia at the Italian hemathology units with access to momelotinib. All participating centers belong to the GIMEMA network.

Trial design

Design model

Case-only

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

93 Participants

are grouped into 1 trial group

Group A: MF patients treated with momelotinib

Trial outcomes

Primary outcomes

Efficacy of momelotinib in splenic response improving

To assess the splenic response in terms of rate of patients with more or equal than 50% palpatory reduction compared to baseline at 6 months.

Time frame

Six months

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Gruppo Italiano Malattie EMatologiche dell'Adulto

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: